Marco Foppoli

Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review

Sara Steffanoni, Teresa Calimeri, Sarah Marktel, Rosamaria Nitti et autres

BACKGROUND: Consolidation therapy has improved the outcome of newly diagnosed PCNSL patients. Whole-brain radiotherapy (WBRT) was the first consolidation strategy used and represented the gold standard for many years, but at the expense of a high risk of neurotoxicity. Thus, alternative strategies …

it (code pays fourni par la source)

780 POTENTIAL RELATIONSHIP BETWEEN MITOCHONDRIAL FERRITIN EXPRESSION AND CARDIOTOXICITY IN PATIENTS UNDERGOING ANTHRACYLINE CHEMOTHERAPY

Giulia Marchionni, Sonia Levi, Andrea Pontara, Paolo Santambrogio et autres

Abstract Background Anthracyclines effectiveness is burdened by numerous side effects, among which cardiotoxicity (CTX) is the one carrying the highest impact on survival. Prevention of CTX is known to be far more effective than its treatment. Nonetheless, present patients stratification does not …

it (code pays fourni par la source)

Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma

Andrés J.M. Ferreri, Piera Angelillo, Federico Erbella, Chiara M. Cattaneo et autres

Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). In the last decade, 68 patients with Burkitt lymphoma ([BL] n = 46) or high-grade B-cell lymphoma ([HGBCL] single, …

it (code pays fourni par la source)

Development of a whole-body physiologically-based pharmacokinetic model for high-dose methotrexate

Giuseppe Pesenti, Dario Massari, Marco Foppoli, Davide Manca

it (code pays fourni par la source)

Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma

Teresa Calimeri, Sara Steffanoni, Marco Foppoli, Maurilio Ponzoni et autres

Introduction: Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) represents a relevant challenge in onco-hematology. PCNSL has specific molecular profile and biological characteristics that distinguish it from systemic DLBCL. Several translational studies have allowed for significant improvement in …

it (code pays fourni par la source)

Optimal dose and uncertainty estimation for individualized drug administration using pharmacokinetic models

Giuseppe Pesenti, Marco Foppoli, Davide Manca

it (code pays fourni par la source)

A minimal physiologically based pharmacokinetic model for high-dose methotrexate

Giuseppe Pesenti, Marco Foppoli, Davide Manca

PURPOSE: High-dose methotrexate (HDMTX) is administered for the treatment of a variety of malignant tumors. Wide intra- and inter-individual variabilities characterize the pharmacokinetics of MTX, which is mostly excreted renally. HDMTX dosages are prescribed as a function of body surface area whereas …

it (code pays fourni par la source)

SAFETY AND EFFICACY OF THE “CARMEN” REGIMEN, A NEW DOSE‐DENSE SHORT‐TERM THERAPY IN PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA AND MYC REARRANGEMENT

Andrés J.M. Ferreri, Piera Angelillo, Federico Erbella, Carmine Liberatore et autres

Cohort 1 (57%) and progression/death (69%) in Cohort 2. Treatment was delayed ≥7D in 11 cycles (3%) in Cohort 1 and 12 (6%) in Cohort 2. Doxorubicin and/or cyclophosphamide were dose-reduced in 9 cycles (2%) in Cohort 1 and 12 (4%) in …

it (code pays fourni par la source)

PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT

Andrés J.M. Ferreri, Vittoria Tarantino, G. Cabras, Felicetto Ferrara et autres

Introduction: CNS dissemination is an uncommon event in PMLBCL. International cooperation is an important tool to improve our knowledge on this poorly-investigated condition. Methods: Data from PMLBCL pts with CNS disease at presentation or relapse treated at 24 Centers from 6 countries …

it, gb, br, us, gr (code pays fourni par la source)

MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study

Andrés J.M. Ferreri, Teresa Calimeri, Paolo Lopedote, Ilaria Francaviglia et autres

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) …

it, us (code pays fourni par la source)

A dose‐dense short‐term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high‐risk Burkitt lymphoma or high‐grade B‐cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial

Andrés J.M. Ferreri, Chiara M. Cattaneo, Arben Lleshi, Luisa Verga et autres

A few prospective trials in HIV-positive patients with Burkitt lymphoma (BL) or high-grade B-cell lymphoma (HGBL) have been reported. Investigated therapies have shown good efficacy but relevant safety problems, with high rates of interruptions, severe mucositis, septic complications, and fungal infections. Here, …

it, us (code pays fourni par la source)

Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial

Andrés J.M. Ferreri, Teresa Calimeri, Maurilio Ponzoni, Flavio Curnis et autres

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment of diffuse large B-cell lymphoma (DLBCL). Primary DLBCL of the central nervous system (CNS) (primary central nervous system lymphoma [PCNSL]) is an exception because of the low CNS bioavailability of related …

it, us (code pays fourni par la source)